Resource for Clinical Studies of AKI (Clinical Research/Genomics/Biorepository)

项目摘要(见说明)：急性肾损伤(AKI)的临床和转化性研究需要精心设计的前瞻性研究，以及能够接触到具有良好特征的患者，并进行纵向随访和生物样本，使研究人员能够探索影响结果的潜在机制和途径。AKI临床研究资源(核心A)的具体目标是：1)提供核心资源，支持AKI临床研究的设计和实施；2)提供基因组学资源，进行系统的基因组分析并与临床表型信息相关联；3)为我们的研究人员提供与临床和基因组学数据库相连的生物样本库，以确定患者的特征。这一核心将特别为研究人员提供通过一个已建立的国际合作调查人员网络接触AKI患者的机会，这些合作调查人员正在为目前有1000多名患者的ICU环境中的AKI登记做出贡献，可以获得包括患者和健康对照在内的生物样本，以及用于定量评估肾功能变化的方案和工具。自成立以来，核心一直成功地支持临床和转化性研究的研究人员。该中心已经建立了一个强大的AKI患者数据管理系统和数据库，可以灵活地适应单个研究人员和合作中心的研究目标；目前支持5个大型多中心项目，包括AKI注册和一项针对药物引起的肾损伤的基因组学的国际前瞻性研究。基因组学资源促进了对AKI的遗传决定因素(风险和结果)的研究，并确定了AKI纵向过程的新的基因组预测因子。已经进行了14,000多项包含20多种分析物的生物标记物分析，以支持儿科和成人AKI研究。已经建立了一个生物样本库，拥有来自具有良好特征的AKI患者和没有AKI患者的2000个序列样本。核心为52名调查员支助了143个项目(包括4名试点获奖者和45名非核心人员)，出版了57份出版物。这些丰富的资源将继续推动AKI的跨学科临床研究，促进我们对人类AKI的自然历史、病理生理学和治疗的了解。CORE A与UAB和UCSD的现有资源以及奥布莱恩中心内的其他核心一起，将加快新的研究见解的转化，以改善AKI患者的结果。

PROJECT SUMMARY (See instructions): Clinical and translational research in acute kidney injury (AKI) requires well designed prospective studies as well as access to well characterized patients with longitudinal follow up coupled with biological samples enabling investigators to probe the underlying mechanisms and pathways contributing to outcomes. The specific aims of the Resource for Clinical Studies of AKI (Core A) are to 1) provide core resources to support the design and conduct of clinical research In AKI, 2) provide a genomics resource to perform systematic genomic analyses and allow correlation with clinical phenotypic information, and 3) provide a biological sample repository linked to the clinical and genomics database for the characterization of patients for our investigator base. This core will specifically provide investigators access to patients with AKI through an established international network of collaborating investigators who are contributing to an ongoing registry of AKI in the ICU setting currently with over 1000 patients, access to biological samples including DNA from patients and healthy controls and protocols and tools for quantitative assessment of changes in kidney function. Since its inception the Core has been successful in supporting investigators for clinical and translational research. The Core has established a robust data management system and database of patients with AKI that Is flexible In accommodating the research objectives of individual investigators and collaborating centers; currently supporting 5 large multicenter projects including the AKI registry and an international prospective study for the genomics of drug-induced kidney injury. The genomics resource has facilitated the investigation of genetic determinants (both risk and outcome) of AKI, and identified novel genomic predictors of the longitudinal course in AKI. Over 14,000 biomarker assays incorporating more than 20 analytes have been performed to support both pediatric and adult AKI research. A biological sample repository has been established and has >2000 sequential samples from well-characterized patients with and without AKI. The Core has supported 143 projects for 52 investigators (including 4 pilot recipients and 45 non-core personnel), resulting in 57 publications. These rich resources will continue to enable interdisciplinary clinical investigation in AKI to advance our understanding of the natural history, pathophysiology and treatment of human AKI. Core A in conjunction with existing resources at UAB and UCSD and other cores within the O'Brien center will accelerate the translation of new investigative insights towards improving outcomes for patients with AKI.